IL158739A0 - Anti-virus agent - Google Patents

Anti-virus agent

Info

Publication number
IL158739A0
IL158739A0 IL15873902A IL15873902A IL158739A0 IL 158739 A0 IL158739 A0 IL 158739A0 IL 15873902 A IL15873902 A IL 15873902A IL 15873902 A IL15873902 A IL 15873902A IL 158739 A0 IL158739 A0 IL 158739A0
Authority
IL
Israel
Prior art keywords
virus agent
present
virus
construct
gene encoding
Prior art date
Application number
IL15873902A
Other languages
English (en)
Original Assignee
Technologie Integrale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Integrale Ltd filed Critical Technologie Integrale Ltd
Publication of IL158739A0 publication Critical patent/IL158739A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL15873902A 2001-05-04 2002-04-30 Anti-virus agent IL158739A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/848,269 US20030176372A1 (en) 2001-05-04 2001-05-04 Anti-virus agent
EP01110873A EP1254663B1 (en) 2001-05-04 2001-05-04 Anti-virus agent
PCT/EP2002/004774 WO2002089817A2 (en) 2001-05-04 2002-04-30 Anti-virus agent

Publications (1)

Publication Number Publication Date
IL158739A0 true IL158739A0 (en) 2004-05-12

Family

ID=46679311

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15873902A IL158739A0 (en) 2001-05-04 2002-04-30 Anti-virus agent

Country Status (15)

Country Link
US (1) US20030176372A1 (hu)
EP (1) EP1254663B1 (hu)
JP (1) JP2005510455A (hu)
CN (1) CN1527716A (hu)
AT (1) ATE281838T1 (hu)
CA (1) CA2446204A1 (hu)
CZ (1) CZ20033288A3 (hu)
DE (1) DE60107052T2 (hu)
DK (1) DK1254663T3 (hu)
ES (1) ES2234730T3 (hu)
HU (1) HUP0400987A3 (hu)
IL (1) IL158739A0 (hu)
PL (1) PL367451A1 (hu)
PT (1) PT1254663E (hu)
WO (1) WO2002089817A2 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137415A1 (en) * 2007-04-20 2010-06-03 Takara Bio Inc. Vector for gene therapy
WO2017131079A1 (ja) * 2016-01-27 2017-08-03 国立大学法人北海道大学 ウイルスフリー植物体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973507A (en) * 1989-01-23 1990-11-27 Horian Richard C Thin wood laminate panel and method of fabrication
EP0479180A3 (en) * 1990-10-05 1992-08-26 Hoechst Aktiengesellschaft Virus resistant plants, method for their production

Also Published As

Publication number Publication date
ES2234730T3 (es) 2005-07-01
US20030176372A1 (en) 2003-09-18
CZ20033288A3 (cs) 2004-04-14
CN1527716A (zh) 2004-09-08
WO2002089817A3 (en) 2003-01-30
CA2446204A1 (en) 2002-11-14
HUP0400987A2 (hu) 2004-08-30
WO2002089817A2 (en) 2002-11-14
DK1254663T3 (da) 2005-03-21
ATE281838T1 (de) 2004-11-15
PL367451A1 (en) 2005-02-21
EP1254663B1 (en) 2004-11-10
HUP0400987A3 (en) 2004-10-28
PT1254663E (pt) 2005-04-29
DE60107052D1 (de) 2004-12-16
DE60107052T2 (de) 2005-11-24
EP1254663A1 (en) 2002-11-06
JP2005510455A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
EP1016418A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
EP1829547A3 (en) Treatment of neurodegenerative disease through intracranial delivery of short interfering RNA (siRNA)
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
EA200701450A1 (ru) РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
WO2005030800A3 (en) Oligonucleotide analog and method for treating flavivirus infections
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
MXPA01010392A (es) Produccion de vacunas de virus con arn de hebra negativa atenuados a partir de secuencias de nucleotidos clonadas.
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
ATE457359T1 (de) Auf lps-reagierendes chs1/beige-ähnliches anker- gen und therapeutische anwendungen davon
WO2005013905A3 (en) SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
ATE294866T1 (de) Zellen, die virus-resistent und von viren infizierbar sind
IL158739A0 (en) Anti-virus agent
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
JP2008503569A5 (hu)
SE9804298D0 (sv) New medical use
EA200301089A1 (ru) Противовирусный агент
HK1002983A1 (en) Diagnostic and therapeutic system
PL370854A1 (en) Ee3-protein family and corresponding dna sequences
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
CA2086577A1 (en) Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene
Elmén Nucleic acid based therapeutic approaches
Houlton Silence is golden.
AU3956100A (en) Rna polymerase i transcription factor tif-ia